{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:43:51Z","timestamp":1787028231922,"version":"build-2736575974"},"reference-count":26,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T00:00:00Z","timestamp":1626307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R15GM137449"],"award-info":[{"award-number":["R15GM137449"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Background: Advancement in genome engineering enables rapid and targeted disruption of any coding sequences to study gene functions or establish human disease models. We explored whether this approach can be used to study Gaucher disease, one of the most common types of lysosomal storage diseases (LSDs) in a near-haploid human cell line (HAP1). Results: CRISPR-Cas9 targeting to coding sequences of \u03b2-glucocerebrosidase (GBA), the causative gene of Gaucher disease, resulted in an insertional mutation and premature termination of GBA. We confirmed the GBA knockout at both the gene and enzyme levels by genotyping and GBA enzymatic assay. Characterization of the knockout line showed no significant changes in cell morphology and growth. Lysosomal staining revealed more granular lysosomes in the cytosol of the GBA-knockout line compared to its parental control. Flow cytometry analysis further confirmed that more lysosomes accumulated in the cytosol of the knockout line, recapturing the disease phenotype. Finally, we showed that this knockout cell line could be used to evaluate a replacement therapy by recombinant human GBA. Conclusions: Targeted gene disruption in human HAP1 cells enables rapid establishment of the Gaucher model to capture the key pathology and to test replacement therapy. We expect that this streamlined method can be used to generate human disease models of other LSDs, most of which are still lacking both appropriate human disease models and specific treatments to date.<\/jats:p>","DOI":"10.3390\/genes12071076","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T09:32:07Z","timestamp":1626341527000},"page":"1076","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recapture Lysosomal Enzyme Deficiency via Targeted Gene Disruption in the Human Near-Haploid Cell Line HAP1"],"prefix":"10.3390","volume":"12","author":[{"given":"Annie","family":"Brown","sequence":"first","affiliation":[{"name":"Department of Bioengineering, School of Engineering, Santa Clara University, 500 El Camino Real, Santa Clara, CA 95053, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, School of Engineering, Santa Clara University, 500 El Camino Real, Santa Clara, CA 95053, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Lawler","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, School of Engineering, Santa Clara University, 500 El Camino Real, Santa Clara, CA 95053, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, School of Engineering, Santa Clara University, 500 El Camino Real, Santa Clara, CA 95053, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/MOP.0b013e3282f161f2","article-title":"Enzyme reconstitution\/replacement therapy for lysosomal storage diseases","volume":"19","author":"Burrow","year":"2007","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/GIM.0b013e318211a7e1","article-title":"Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals","volume":"13","author":"Wang","year":"2011","journal-title":"Genet. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1097\/MOP.0b013e32834c20d9","article-title":"Enzyme replacement therapy for lysosomal storage diseases","volume":"23","author":"Lachmann","year":"2011","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","article-title":"Lysosomal storage diseases: From pathophysiology to therapy","volume":"66","author":"Parenti","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nrm1423","article-title":"The cell biology of lysosomal storage disorders","volume":"5","author":"Futerman","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s10545-006-0239-6","article-title":"Limitations of enzyme replacement therapy: Current and future","volume":"29","author":"Wraith","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1242\/dmm.008185","article-title":"Animal models for Gaucher disease research","volume":"4","author":"Vitner","year":"2011","journal-title":"Dis. Models Mech."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"13819","DOI":"10.1073\/pnas.0606016103","article-title":"Effective cell and gene therapy in a murine model of Gaucher disease","volume":"103","author":"Enquist","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1177\/030098587301000302","article-title":"Neurovisceral glucocerebroside storage (Gaucher\u2019s disease) in a dog","volume":"10","author":"Hartley","year":"1973","journal-title":"Vet. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nbt.2800","article-title":"Genome-wide recessive genetic screening in mammalian cells with a lentiviral CRISPR-guide RNA library","volume":"32","author":"Li","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nbt.2507","article-title":"Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease","volume":"31","author":"Cho","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1146\/annurev-genom-091212-153435","article-title":"Genome engineering at the dawn of the golden age","volume":"14","author":"Segal","year":"2013","journal-title":"Annu. Rev. Genom. Hum. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.cell.2014.05.010","article-title":"Development and Applications of CRISPR-Cas9 for Genome Engineering","volume":"157","author":"Hsu","year":"2014","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1261\/rna.042010.113","article-title":"A TALEN-based strategy for efficient bi-allelic miRNA ablation in human cells","volume":"20","author":"Sarkar","year":"2014","journal-title":"RNA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.tibtech.2013.04.004","article-title":"ZFN, TALEN, and CRISPR\/Cas-based methods for genome engineering","volume":"31","author":"Gaj","year":"2013","journal-title":"Trends Biotechnol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1178955","article-title":"Haploid Genetic Screens in Human Cells Identify Host Factors Used by Pathogens","volume":"326","author":"Carette","year":"2009","journal-title":"Science"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/nbt.1857","article-title":"Global gene disruption in human cells to assign genes to phenotypes by deep sequencing","volume":"29","author":"Carette","year":"2011","journal-title":"Nat. Biotechnol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/humu.20676","article-title":"Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)","volume":"29","author":"Hruska","year":"2008","journal-title":"Hum. Mutat."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(08)61522-6","article-title":"Phenotype, diagnosis, and treatment of Gaucher\u2019s disease","volume":"372","author":"Grabowski","year":"2008","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1073\/pnas.87.5.1913","article-title":"Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease","volume":"87","author":"Barton","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1517\/14712590802573395","article-title":"Enzyme replacement therapy for Gaucher disease","volume":"9","author":"Charrow","year":"2008","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-53844-5","article-title":"Targeted delivery of lysosomal enzymes to the endocytic compartment in human cells using engineered extracellular vesicles","volume":"9","author":"Do","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"D200","DOI":"10.1093\/nar\/gkw1129","article-title":"CDD\/SPARCLE: Functional classification of proteins via subfamily domain architectures","volume":"45","author":"Bo","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s10930-019-09838-3","article-title":"A Brief History of Protein Sorting Prediction","volume":"38","author":"Nielsen","year":"2019","journal-title":"Protein J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nmeth.3113","article-title":"Genome engineering: The next genomic revolution","volume":"11","author":"Gersbach","year":"2014","journal-title":"Nat. Methods"}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/7\/1076\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:30:56Z","timestamp":1760164256000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/12\/7\/1076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,15]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["genes12071076"],"URL":"https:\/\/doi.org\/10.3390\/genes12071076","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,15]]}}}